Congress Materials

TRULANCE®

(plecanatide) 3 mg tablets

IBS-C

American College of Gastroenterology (ACG) Annual Scientific Meeting 2022—October 21–26, 2022, Charlotte, NC

Plecanatide improves severe abdominal pain and severe bloating in individuals with irritable bowel syndrome with constipation: a pooled analysis of two phase 3 trials

Sayuk G, et al.

Plecanatide improves symptoms of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C) across age subgroups: an analysis of four phase 3 trials

Staller K, et al.

AAFP FMX 2022—September 20–23, 2022, Washington, DC

Plecanatide produces a more rapid and sustained clinical response compared with placebo in patients with irritable bowel syndrome with constipation  [Encore]

Shah E, et al.

Digestive Disease Week (DDW) 2022—May 21–24, 2022, San Diego, CA + Virtual

Plecanatide produces a more rapid and sustained clinical response compared to placebo in patients with irritable bowel syndrome with constipation

Shah ED, et al.

American College of Gastroenterology (ACG) Annual Scientific Meeting 2021—October 22–27, 2021, Las Vegas, NV

Plecanatide provided clinically meaningful improvements in health-related quality of life in patients with chronic idiopathic constipation and irritable bowel syndrome with constipation: a post-hoc analysis

Brenner DM, et al.

Plecanatide improves abdominal symptoms in individuals with chronic idiopathic constipation and irritable bowel syndrome with constipation, including those experiencing severe bloating, pain, and discomfort

Sayuk GS, et al.

American Neurogastroenterology and Motility Society (ANMS) Annual Meeting 2021—August 13–15, 2021, Boston, MA

Treatment satisfaction and improvement in quality of life with plecanatide among patients with chronic idiopathic constipation and irritable bowel syndrome with constipation: analyses from four phase 3 trials

Brenner DM, et al.

Plecanatide is effective in severely constipated patients with chronic idiopathic constipation and irritable bowel syndrome with constipation

Cash B , et al.

American Association of Nurse Practitioners (AANP) National Conference 2021—June 15–August 31, 2021, Online

Plecanatide provides meaningful improvements in patients with chronic idiopathic constipation and irritable bowel syndrome with constipation reporting reduced quality of life: analyses from four randomized phase 3 trials [Encore]

Brenner DM, et al.

Digestive Disease Week (DDW) 2021—May 21–23, 2021, Virtual

Plecanatide provides meaningful improvements in patients with chronic idiopathic constipation and irritable bowel syndrome with constipation reporting reduced quality of life: analyses from four randomized phase 3 trials

Brenner DM, et al.

Gastroenterology & Hepatology Advanced Practice Providers (GHAPP) Annual Conference 2020—November 19–21, 2020, Las Vegas, NV

Plecanatide significantly reduces global symptoms, abdominal pain, and bloating in individuals with irritable bowel syndrome with constipation experiencing varying levels of abdominal pain and bloating at baseline

Bharucha AE, et al.

The impact of plecanatide on patient-reported assessments of disease severity, quality of life, and treatment satisfaction in adults with irritable bowel syndrome with constipation  [Encore]

Chang C, et al.

American Pharmacists Association (APhA) Annual Meeting & Exposition 2020—October 24–28, 2020, Virtual

Pharmacist consultation in individuals with chronic idiopathic constipation or irritable bowel syndrome with constipation: results from the BURDEN-CIC and BURDEN IBS-C surveys [Encore]

Quigley EMM, et al.

American College of Gastroenterology (ACG) Annual Scientific Meeting 2020—October 23–28, 2020, Virtual

The impact of plecanatide on abdominal pain in patients with chronic idiopathic constipation and irritable bowel syndrome with constipation: analysis from four phase 3 studies

Barucha A, et al.

Efficacy of plecanatide in bloated patients with chronic idiopathic constipation and moderately to severely bloated patients with irritable bowel syndrome with constipation

Brenner DM, et al.

Efficacy and safety of plecanatide in patients with chronic idiopathic constipation or irritable bowel syndrome with constipation: intrinsic factors analyses from four studies

Chang C, et al.

AMCP Nexus 2020—October 19–23, 2020, Virtual

The impact of plecanatide on patient-reported assessments of disease severity, quality of life, and treatment satisfaction in adults with irritable bowel syndrome with constipation

Chang C, et al.

Efficacy and safety of plecanatide in patients with irritable bowel syndrome with constipation: per protocol analysis of two pooled, randomized phase 3 studies  [Encore]

Sharma A, et al.

Pharmacist consultation in individuals with chronic idiopathic constipation or irritable bowel syndrome with constipation: results from the BURDEN-CIC and BURDEN IBS-C surveys [Encore]

Weaver J, et al.

United European Gastroenterology (UEG) Week 2020—October 11–13, 2020, Virtual

Early response to plecanatide predicts overall and sustained efficacy in patients with irritable bowel syndrome with constipation

Martinez de Andino N, et al.

Digestive Disease Week (DDW) 2020—May 2–5, 2020, Virtual

Plecanatide for patients with chronic idiopathic constipation and irritable bowel syndrome-constipation: analysis of abdominal pain from four randomized phase 3 clinical trials

Bharucha AE, et al.

Plecanatide for patients with chronic idiopathic constipation and irritable bowel syndrome–constipation: analysis of symptoms' responses by baseline bloating severity from four randomized phase 3 clinical trials

Brenner DM, et al.

Safety and efficacy evaluation of plecanatide for the treatment of chronic idiopathic constipation and irritable bowel syndrome-constipation in patients aged 65 years or older

Menees S, et al.

American College of Managed Care Pharmacy (AMCP) 2020—April 21–24, 2020, Meeting Cancelled

Efficacy and safety of plecanatide in patients with irritable bowel syndrome with constipation: per protocol analysis of 2 pooled, randomized phase 3 studies

Sharma A, et al.

Pharmacist consultation in individuals with chronic idiopathic constipation or irritable bowel syndrome with constipation: results from the BURDEN-CIC and BURDEN IBS-C surveys

Weaver J, et al.

American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting and Exhibition 2019—December 8–12, 2019, Las Vegas, NV

Efficacy and safety of plecanatide in patients with irritable bowel syndrome with constipation: pooled analysis of 2 randomized clinical trials  [Encore]

Franklin H, et al.

AMCP Nexus 2019—October 29–November 1, 2019, National Harbor, MD

Plecanatide improved patient global assessment of IBS symptoms in adult patients with IBS-C

Chang C, et al.

American College of Gastroenterology (ACG) Annual Scientific Meeting 2019—October 25–30, 2019, San Antonio, TX

Plecanatide for patients with chronic idiopathic constipation and irritable bowel syndrome-constipation: analysis of abdominal bloating from four randomized phase 3 clinical trials

Franklin H, et al.

Gastroenterology & Hepatology Advanced Practice Providers (GHAPP) Annual Conference 2019—September 5–7, 2019, Las Vegas, NV

Efficacy of plecanatide for patients with chronic idiopathic constipation and irritable bowel syndrome–constipation with abdominal bloating: analysis from four randomized phase 3 clinical trials

Brenner D, et al.

Efficacy and safety of plecanatide in patients with irritable bowel syndrome with constipation: pooled analysis of 2 randomized clinical trials [Encore]

Franklin H, et al.

Digestive Disease Week (DDW) 2019—May 18–21, 2019, San Diego, CA

Plecanatide improved patient global rating of IBS symptoms in adult patients with IBS-C

Chang C, et al.

Communication between clinicians and patients with chronic idiopathic constipation or irritable bowel syndrome with constipation: an ethnographic study of office visits

Sayuk GS, et al.

American College of Gastroenterology (ACG) Annual Scientific Meeting 2018—October 5–10, 2018, Philadelphia, PA

Evaluation of the safety and tolerability of plecanatide in CIC and IBS-C patients aged 65 and older

Menees SB, et al.

Digestive Disease Week (DDW) 2018—June 2–5, 2018, Washington, DC

Safety, tolerability, and effectiveness of plecanatide in patients with constipation-predominant irritable bowel syndrome: long-term evidence from an open-label study

Barish CF, et al.

Efficacy of plecanatide for the treatment of irritable bowel syndrome with constipation: use of radar plots to express aggregated multivariate results from two phase III placebo-controlled trials

Brenner DM, et al.

American College of Gastroenterology (ACG) Annual Scientific Meeting 2017—October 13–18, 2017, Orlando, FL

Efficacy and safety of plecanatide in patients with irritable bowel syndrome with constipation: pooled analysis of 2 randomized clinical trials

Krause R, et al.

The BURDEN IBS-C study (Better Understanding and Recognition of the Disconnects, Experiences, and Needs of Patients with Irritable Bowel Syndrome with Constipation)

Quigley EMM, et al.

Digestive Disease Week (DDW) 2017—May 6–9, 2017, Chicago, IL

Efficacy and safety of plecanatide in patients with irritable bowel syndrome with constipation: results from 2 randomized, double-blind, placebo-controlled clinical trials

Fogel R, et al.

The uroguanylin analog plecanatide activates guanylate cyclase-C predominantly in the lumen of the proximal small intestine to stimulate chloride and fluid secretion and increase GI transit in animal models

Joshi A, et al.

Plecanatide and dolcanatide, guanylate cyclase-C agonists, attenuate paracellular permeability and enhance normal localization of tight junctional proteins to maintain intestinal barrier function

Thadi A, et al.

Digestive Disease Week (DDW) 2016—May 22–24, 2016, San Diego, CA

Structural and dynamic features of plecanatide: insights from molecular dynamics simulations

Brancale A, et al.

Plecanatide, like uroguanylin, activates guanylate cyclase-C signaling in a pH-dependent manner in T84 cells, and in murine intestinal epithelial cells and tissues

Patwa V, et al.

American College of Gastroenterology (ACG) Annual Scientific Meeting 2014—October 17–22, 2014, Philadelphia, PA

Plecanatide, a novel uroguanylin analog: a 12-week, randomized, double-blind, placebo-controlled, dose-ranging trial to evaluate efficacy and safety in patients with irritable bowel syndrome with constipation

Miner P, et al.

United European Gastroenterology (UEG) Week 2012—October 20–24, 2012, Amsterdam, the Netherlands

Orally administered plecanatide, a guanylate cyclase-C agonist, acts in the proximal intestine to stimulate fluid secretion to normalize bowel movement

Comiskey S, et al.

American College of Gastroenterology (ACG) Annual Scientific Meeting 2012—October 19–24, 2012, Las Vegas, NV

Orally administered plecanatide, a guanylate cyclase-C agonist, acts in the lumen of the proximal intestine to facilitate normal bowel movement in mice and monkeys

Comiskey S, et al.

Joint International Neurogastroenterology and Motility Meeting 2012—September 6–8, Bologna, Italy, 2012

Plecanatide, a superior analog of uroguanylin, as an oral drug candidate for treatment of gastrointestinal functional disorders and diseases

Shailubhai K, et al.

American College of Gastroenterology (ACG) Annual Scientific Meeting 2011—October 28–November 2, 2011, Washington, DC

A comparison of the physical and pharmacological properties of plecanatide (SP-304) and the human hormone uroguanylin

Solinga R, et al.

View product- and therapeutic area—related publications appearing in peer-reviewed journals.

Search

*Required field.

Select a product*

Select

Select a therapeutic area*

Select

Enter keyword(s)